Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors

P T. 2016 Jan;41(1):28-53.

Authors

Marina Manniello, Michele Pisano

PMID: 26766888
PMCID: PMC4699483

Abstract

Alirocumab (Praluent): first in the new class of PCSK9 inhibitors.